I. Expression across cell types
Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| endothelial cell | 6 studies | 19% ± 2% | |
| fibroblast | 5 studies | 22% ± 4% | |
| T cell | 4 studies | 20% ± 3% | |
| B cell | 3 studies | 24% ± 1% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| endothelial cell | 6 studies | 19% ± 2% | |
| fibroblast | 5 studies | 22% ± 4% | |
| T cell | 4 studies | 20% ± 3% | |
| B cell | 3 studies | 24% ± 1% |
Insufficient scRNA-seq data for expression of NACA2 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| ovary | 99% | 29.12 | 179 / 180 | 97% | 3.86 | 417 / 430 |
| esophagus | 95% | 14.07 | 1378 / 1445 | 99% | 5.23 | 182 / 183 |
| stomach | 89% | 9.53 | 320 / 359 | 82% | 4.44 | 234 / 286 |
| intestine | 95% | 13.57 | 920 / 966 | 63% | 3.44 | 334 / 527 |
| prostate | 98% | 17.60 | 241 / 245 | 36% | 0.64 | 183 / 502 |
| bladder | 100% | 9.71 | 21 / 21 | 29% | 1.26 | 148 / 504 |
| lung | 92% | 12.36 | 534 / 578 | 35% | 1.11 | 408 / 1155 |
| uterus | 96% | 16.76 | 164 / 170 | 30% | 0.57 | 138 / 459 |
| brain | 86% | 9.22 | 2275 / 2642 | 38% | 1.43 | 271 / 705 |
| skin | 97% | 17.40 | 1762 / 1809 | 22% | 0.37 | 106 / 472 |
| thymus | 95% | 14.98 | 618 / 653 | 24% | 0.41 | 143 / 605 |
| adrenal gland | 95% | 14.49 | 244 / 258 | 21% | 0.35 | 48 / 230 |
| breast | 97% | 18.05 | 447 / 459 | 16% | 0.26 | 179 / 1118 |
| kidney | 93% | 11.61 | 83 / 89 | 14% | 0.22 | 128 / 901 |
| pancreas | 90% | 9.42 | 294 / 328 | 10% | 0.12 | 17 / 178 |
| adipose | 97% | 15.77 | 1167 / 1204 | 0% | 0 | 0 / 0 |
| blood vessel | 95% | 13.38 | 1263 / 1335 | 0% | 0 | 0 / 0 |
| spleen | 95% | 10.91 | 228 / 241 | 0% | 0 | 0 / 0 |
| muscle | 88% | 9.97 | 708 / 803 | 0% | 0 | 0 / 0 |
| heart | 86% | 9.08 | 743 / 861 | 0% | 0 | 0 / 0 |
| peripheral blood | 86% | 11.06 | 798 / 929 | 0% | 0 | 0 / 0 |
| liver | 77% | 6.84 | 173 / 226 | 8% | 0.14 | 34 / 406 |
| lymph node | 0% | 0 | 0 / 0 | 41% | 0.87 | 12 / 29 |
| eye | 0% | 0 | 0 / 0 | 24% | 0.35 | 19 / 80 |
| tonsil | 0% | 0 | 0 / 0 | 20% | 0.29 | 9 / 45 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
| GO_0015031 | Biological process | protein transport |
| GO_0006612 | Biological process | protein targeting to membrane |
| GO_0005737 | Cellular component | cytoplasm |
| GO_0005854 | Cellular component | nascent polypeptide-associated complex |
| GO_0005634 | Cellular component | nucleus |
| GO_0051082 | Molecular function | unfolded protein binding |
| Gene name | NACA2 |
| Protein name | Nascent polypeptide-associated complex subunit alpha-2 (Alpha-NAC-like) (Hom s 2.01) (Nascent polypeptide-associated complex subunit alpha-like) (NAC-alpha-like) |
| Synonyms | NACAL |
| Description | FUNCTION: Prevents inappropriate targeting of non-secretory polypeptides to the endoplasmic reticulum (ER). Binds to nascent polypeptide chains as they emerge from the ribosome and blocks their interaction with the signal recognition particle (SRP), which normally targets nascent secretory peptides to the ER. Also reduces the inherent affinity of ribosomes for protein translocation sites in the ER membrane (M sites) (By similarity). . |
| Accessions | ENST00000521764.3 Q9H009 |
